NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Naproxen Sodium And Diphenhydramine Hydrochloride patents expire, and when can generic versions of Naproxen Sodium And Diphenhydramine Hydrochloride launch?
Naproxen Sodium And Diphenhydramine Hydrochloride is a drug marketed by Amneal Pharms Co, Corepharma, Granules, P And L, and Perrigo R And D. and is included in five NDAs.
The generic ingredient in NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE is diphenhydramine hydrochloride; naproxen sodium. There are twenty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride; naproxen sodium profile page.
Summary for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 22 |
Clinical Trials: | 9 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ciusss de L'Est de l'Île de Montréal | N/A |
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Alphacait, LLC | Phase 2 |
See all NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE clinical trials
Pharmacology for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
Drug Class | Histamine-1 Receptor Antagonist Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors Histamine H1 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
US Patents and Regulatory Information for NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amneal Pharms Co | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 209726-001 | Oct 23, 2018 | OTC | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
P And L | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 207597-001 | Jan 25, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Corepharma | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 211830-001 | Aug 22, 2019 | OTC | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Granules | NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE | diphenhydramine hydrochloride; naproxen sodium | TABLET;ORAL | 213663-001 | Sep 24, 2020 | OTC | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |